{"filings":[{"id":372034,"accession_number":"0001477932-22-004371","cik":1603345,"company_name":"Agentix Corp.","ticker":"AGTX","form_type":"8-K","filed_at":"2022-06-14T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Agentix Corp. appoints Salman Hoda to board of directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Salman Hoda appointed to board on June 11, 2022; also serves as Secretary and Treasurer since Dec 2020.","Hoda's consulting entity receives $12,500/month under agreement ending Dec 31, 2022.","Holds 750,000 shares of Agentix common stock through his consulting entity."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":841406.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":409056,"accession_number":"0001477932-21-009384","cik":1603345,"company_name":"Agentix Corp.","ticker":"AGTX","form_type":"8-K","filed_at":"2021-12-21T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Agentix and RTI announce worldwide exclusive license for NAFLD, NASH, T2D, obesity candidates","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["License covers RTI small-molecule candidates for NAFLD, NASH, T2D, and obesity.","Agentix must complete Phase I trials by Jan 15, 2023; Phase II by Oct 2025; Phase III by Oct 2028.","Agentix plans to file IND with FDA in ~12 months; RTI to assist with IND-enabling toxicology and GMP manufacturing.","No financial terms disclosed; pre-clinical data show efficacy in animal models of metabolic diseases."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":841406.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":427977,"accession_number":"0001477932-21-004665","cik":1603345,"company_name":"Agentix Corp.","ticker":"AGTX","form_type":"8-K","filed_at":"2021-07-16T23:59:59+00:00","items":["2.01","9.01"],"status":"ready","headline":"Agentix Corp. completes merger with Applied Biopharma LLC; interests converted to common stock","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Merger completed July 14, 2021: AB Merger LLC merged into Applied Biopharma, with Applied Biopharma surviving.","Each Applied Biopharma LLC interest was converted into one share of Agentix common stock ($0.001 par).","Articles of Merger filed with Nevada Secretary of State on July 14, 2021.","Merger Agreement dated July 13, 2021, previously filed as Exhibit 2.1 to a July 14, 2021 8-K."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":841406.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":427976,"accession_number":"0001477932-21-004619","cik":1603345,"company_name":"Agentix Corp.","ticker":"AGTX","form_type":"8-K","filed_at":"2021-07-14T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Agentix corrects prior filing; enters merger to make Applied BioPharma wholly-owned sub","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Corrects May 27, 2021 8-K to clarify Applied BioPharma was not then a wholly-owned subsidiary.","Enters Merger Agreement (July 13, 2021) with AB Merger LLC to acquire Applied BioPharma for 1 share of common stock.","Articles of Merger executed July 14, 2021, expected to be filed with Nevada Secretary of State on July 15, 2021.","Upon consummation, Applied BioPharma will become a wholly-owned subsidiary of Agentix Corp."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":841406.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}